• Home
  • About us
  • Our products
  • Your health
  • Responsibility
  • In the community
  • Research & development
  • Investors
  • Media centre
  • Careers
GlaxoSmithKline logo

Hazardous waste

In 2004, we disposed of 73.7 million kg of hazardous waste (excluding demolition and construction waste). This is mostly solvents (82.6%), the rest being general site waste (15.3%) and chemical, biological or radioactive waste (2.0%).

In 2004, 50.2% of hazardous waste disposed was incinerated for energy recovery, 47.5% was incinerated without energy recovery. The remaining waste was disposed to licensed landfill sites.

Hazardous waste disposed
chart: Hazardous Waste Disposed

Hazardous waste disposed
Year
Incinerated without energy recovery
Incinerated with energy recovery
Landfill
2001
31.2
28.7
3.4
2002
30.7
28.4
2.8
2003
32.1
26.8
2.2
2004
35.0
37.0
1.9



Per unit sales as percentage of 2001 baseline
2001
2002
2003
2004
2005
100%
94.5%
92.0%
117.3%
185.0%


Hazardous waste source
chart: Hazardous Waste Source

chart: Hazardous Waste Source key


Hazardous waste disposed
 
Solvent waste
Site waste
Others*
2001
50.5
12.7
0.0
2002
50.7
10.3
0.8
2003
48.7
10.5
1.8
2004
60.9
11.3
1.5



Hazardous waste disposed by business
chart: Hazardous Waste Disposed by Business


Hazardous waste disposed by business
Business
2001
2002
2003
2004
01. R&D
1.98
2.78
3.29
3.30
02. Biologicals
2.22
2.53
2.59
3.09
03. Consumer healthcare
0.74
0.95
1.33
1.35
04. New product and global supply
3.65
2.29
2.48
2.20
05. Regional pharma supply
1.71
1.91
1.86
1.70
06. Primary supply and antibiotics
52.46
51.19
49.09
61.83
07. Commercial
0.02
0.14
0.17
0.18
08. Other
0.44
0.07
0.04
0.04

Total hazardous waste disposed increased by 21.0% since 2003 (16.6% since 2001). Hazardous waste disposed per unit sales increased by 27.5% since 2003 (17.3% since 2001) - meaning we are not on track to meet our 2005 target of a 15% reduction per unit sales since 2001.

Our previous trend of reducing hazardous waste per unit sales was reversed in 2004 by a combination of factors. GSK's hazardous waste is mostly solvents and one plant scheduled for closure had to dispose of redundant solvent stocks. This had a one off impact on our data. In addition, changes to production at other plants included bringing in-house processes that were previously undertaken by contract manufacturers. Our engineers will be assessing how to optimise the new processes to reduce solvent use and increase recycling.


* Back to top




This section contains information in several formats:

To download PDF files you will need Adobe Reader. If you do not have it installed, it is available free from the Adobe website. PDF links on this site open in a new window.

For audio-visual content you can use either Windows Media Player or Real Player, which can be installed free from their respective websites.